Leiden University Medical Center

MitoRx Therapeutics Strengthens Scientific Advisory Board with Appointment of Four International Experts

Retrieved on: 
Thursday, March 7, 2024
Therapy, CNRS, Target, Newcastle University, Facial muscles, Biotechnology, Professor, Teaching hospital, SAB, Neuromuscular disease, Ageing, Leiden University Medical Center, HD, DMD, Duchenne muscular dystrophy, Inflammation, LUMC, Mitochondrion, Gene therapy, Scientific method, Genetics, Knowledge, Leibniz Association, Publication, Translational research, Respiratory disease, Research, COPD, Pharmaceutical industry

OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.

Key Points: 
  • OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.
  • Dr. Jon Rees, Chief Executive Officer of MitoRx, said, “We are thrilled to welcome Dr.
  • Le Guiner, Dr. Filipovic, Professor Hansbro, and Professor Aartsma-Rus, to our Scientific Advisory Board.
  • She has a visiting professorship at the John Walton Muscular Dystrophy Research Center at the UK’s Newcastle University.

Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging

Retrieved on: 
Friday, February 23, 2024
Methylation, Dysbiosis, Culture, Penn Center, Health, Bacteria, University, Subtypes of HIV, Life Length, Wistar Institute, Bangladesh Technical Education Board, Ileum, Infection, NIH, AIDS, Glass, Metabolomics, Nucleotide, DSM-IV codes, Biomedical Research, HIV/AIDS research, Wistar, University of Pittsburgh, DNA, Immune system, National Institutes of Health, Leiden University Medical Center, Weill Cornell Medicine, Hannum, Research, Inflammation, Blood, Ageing, Cancer, Cell biology, Microbiome, Rush University, HIV, DNA methylation, Vaccine

Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.

Key Points: 
  • Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.
  • A prime suspect in this aging puzzle is the gut microbiome and its potential leakage into the bloodstream.
  • The Abdel-Mohsen lab investigates how gut leakage can impact the immune system and lead to chronic inflammation, which may accelerate aging.
  • Their analysis revealed a significant connection between disrupted gut microbiomes, increased intestinal permeability (leaky gut), and faster biological aging.

Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD

Retrieved on: 
Thursday, November 30, 2023
NGS, SMCHD1, OGM, Facioscapulohumeral muscular dystrophy, SAN, FSHD, LDT, Mosaic, Laboratory, Leiden University Medical Center, Bombay Hospital, Diagnosis

The study authors assessed the yield of OGM for diagnosing FSHD1 and the ability of next generation sequencing (NGS) to be used as a reflex test to identify FSHD2.

Key Points: 
  • The study authors assessed the yield of OGM for diagnosing FSHD1 and the ability of next generation sequencing (NGS) to be used as a reflex test to identify FSHD2.
  • The study, which included 547 cases with a clinical suspicion of FSHD, used an algorithm that utilized OGM to identify the FSHD haplotype and quantitate the number of D4Z4 repeats found on chromosome 4.
  • “Bionano Laboratories has developed a powerful menu of OGM-based LDTs, including one LDT for FSHD1 diagnosis.
  • We are pleased to see this prestigious group of researchers’ findings from the largest FSHD study to date utilizing OGM.

Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT

Retrieved on: 
Monday, October 30, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Week, IRR, TGCT, Neoplasm, ITT, CSF1R, Leiden University Medical Center, Caregiver, Medicine, Stiffness, ORR, RECIST, Part, Safety, Cancer, Patient, Pharmaceutical industry

“TGCT has a significant negative impact on the daily life of patients who face substantial pain, stiffness, and impaired mobility.

Key Points: 
  • “TGCT has a significant negative impact on the daily life of patients who face substantial pain, stiffness, and impaired mobility.
  • Success across both the primary and all key secondary endpoints in MOTION underscores vimseltinib’s ability to help TGCT patients feel and function better.
  • “The totality of data shown today demonstrate the potential for vimseltinib to offer a new and differentiated treatment option for patients with TGCT.
  • The open-label Part 2 portion of MOTION, in which patients from both the vimseltinib and placebo arms receive treatment with vimseltinib, remains ongoing.

Smart Immune Showcases Data and Presentations at ESGCT

Retrieved on: 
Thursday, October 12, 2023
Congress, Doctor of Philosophy, Leiden University Medical Center, CSO, Sickle cell disease, MD, Cell, Gene, Experiment, University, CEST, Entrepreneurship, Immune system, ESGCT, PID, EIC, European Society of Gene and Cell Therapy, Vaccine

PARIS, France, 12 October 2023 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell progenitor therapy platform to fully and rapidly re-arm the immune system, announced today a series of activities in and around the European Society of Gene and Cell Therapy (ESGCT) 30th Annual Congress being held in Brussels, Belgium from October 24-27, 2023.

Key Points: 
  • PARIS, France, 12 October 2023 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell progenitor therapy platform to fully and rapidly re-arm the immune system, announced today a series of activities in and around the European Society of Gene and Cell Therapy (ESGCT) 30th Annual Congress being held in Brussels, Belgium from October 24-27, 2023.
  • Attended by Smart Immune’s Chief Executive Officer Karine Rossignol and other members of Smart Immune’s team.
  • Karine Rossignol, Chief Executive Officer of Smart Immune, said: “We are excited to be at the ESGCT congress.
  • Our team will be attending a range of activities including an oral presentation by our CSO, and our participation in the EIC Cell and Gene Therapy symposium as one of the EIC accelerator laureates.”
    If you would like to meet with the Smart Immune team during the congress, or at any other time, please contact: [email protected]

OKRA.ai, an Envision Pharma Group Company, Appoints Dr. Yahya Anvar to Senior Leadership Position

Retrieved on: 
Thursday, June 15, 2023
Envision, Science, Data science, Anvar, Doctor of Philosophy, Acquisition, Patient, Master of Science, Pleasure, Artificial intelligence, Brunel University London, Faculty, AI, Health, Leiden University Medical Center, Computational biology, Leiden University, Medical device, Medicine

PHILADELPHIA, PA, June 15, 2023 - (ACN Newswire) - OKRA.ai, an Envision Pharma Group (Envision) company, has appointed senior leader Dr. Yahya Anvar as Chief of AI Science & Insights to unleash the full potential of artificial intelligence (AI) and to further support the life sciences industry.

Key Points: 
  • PHILADELPHIA, PA, June 15, 2023 - (ACN Newswire) - OKRA.ai, an Envision Pharma Group (Envision) company, has appointed senior leader Dr. Yahya Anvar as Chief of AI Science & Insights to unleash the full potential of artificial intelligence (AI) and to further support the life sciences industry.
  • "I am excited about continuing the innovative collaboration between Envision and OKRA.ai along with Yahya as a senior leader as it further solidifies our Envision commitment to the expansion of OKRA.ai and leadership in the AI and technical space," shares Meg Heim, CEO of Envision Pharma Group.
  • His role has now expanded to cover AI insights and scientific expertise across the entire Envision organization following our recent acquisition.
  • I look forward to working with him in driving AI innovation and propelling Envision to new heights."

Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert

Retrieved on: 
Friday, July 28, 2023
Xylazine, University, Naloxone, Leiden University Medical Center, Tennessee Bureau of Investigation, Opioid overdose, Research, Doctor of Philosophy, ADMP, Parent, Trial of the century, Incidence, MD, Drug, Poisoning, Hypoventilation, Patient, Hearing, SAN, FDA, LUMC, Regulation of tobacco by the U.S. Food and Drug Administration, Fentanyl, Food, Anesthesiology, Pharmaceutical industry, Anesthesia, Adamis

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.

Key Points: 
  • SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.
  • The funding will support the work of Albert Dahan, MD, PhD, a world expert on opioid-induced respiratory depression (opioid overdose) and professor of anesthesiology at the University.
  • Dr. Dahan has been working with the FDA since 2020 to understand better methods of reversing fentanyl overdoses.
  • Samuel P. Chapman, Director of Parents for Safer Children, stated, “Prescription strength ZIMHI is the best remedy available for opioid overdose.

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease

Retrieved on: 
Thursday, June 22, 2023
Mayo Clinic, University, PD, Serum, The Michael J. Fox Foundation, Immune tolerance, CAPE, Brain, Movement disorder, Doctor of Philosophy, Immunotherapy, Antibody, 2008 Checker O'Reilly Auto Parts 500, Cerebrospinal fluid, Șaeș, MD, Patient, Alpha-synuclein, Observation, CSF, Ageing, Clinical professor, III, Leiden University Medical Center, Synucleinopathy, CHDR, Safety, Conditional sentence, Höhn, Vaccine, Pharmaceutical industry, Part

CAPE CANAVERAL, Fla., June 22, 2023 (GLOBE NEWSWIRE) --  Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines today announced positive results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson’s disease (PD), demonstrating UB-312 was well-tolerated and induced anti-alpha-synuclein (aSyn) antibody responses in participants with early PD, meeting the primary objectives of the trial.

Key Points: 
  • Results are consistent with conclusions from Phase 1 Part A and preclinical studies, and support advancement of UB-312 into further clinical development.
  • “These positive Phase 1 results demonstrate several important features necessary for an immunotherapy against Parkinson’s disease and other synucleinopathies to be successful, and represent a further proof-of-principle for Vaxxinity’s platform in chronic disease,” said Mei Mei Hu, CEO of Vaxxinity.
  • “UB-312 was observed to safely break immune tolerance, inducing antibodies against toxic aggregated forms of alpha-synuclein.
  • Together these results support the further development of UB-312 in a Phase 2 clinical trial.

ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting

Retrieved on: 
Thursday, April 27, 2023
Vaccine, Infection, SLP, Leiden University Medical Center, SARS-CoV-2, B.V, Immunotherapy, Person, Patient, Immune system, Cancer, ISA, Mouse, Immunodeficiency, Therapy, LUMC, CHDR, CIMT

ISA106, a SARS-CoV-2 immunotherapeutic, consists of multiple SLPs derived from the S, N and M proteins, carefully designed for optimal immunogenicity, administration and manufacturability.

Key Points: 
  • ISA106, a SARS-CoV-2 immunotherapeutic, consists of multiple SLPs derived from the S, N and M proteins, carefully designed for optimal immunogenicity, administration and manufacturability.
  • These are demonstrable ex vivo in peripheral blood mononuclear cells (PBMCs) from convalescent donors who recovered from SARS-CoV-2 infection.
  • The data support further development of ISA106 for the protection of immunocompromised people for whom currently approved SARS-CoV-2 vaccines are insufficiently protective."
  • If you would like to meet with ISA Pharmaceuticals at the above event, please contact us at [email protected] .

ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting

Retrieved on: 
Thursday, April 27, 2023
Vaccine, Infection, SLP, Leiden University Medical Center, SARS-CoV-2, B.V, Immunotherapy, Person, Patient, Immune system, Cancer, ISA, Mouse, Immunodeficiency, Therapy, LUMC, CHDR, CIMT

ISA106, a SARS-CoV-2 immunotherapeutic, consists of multiple SLPs derived from the S, N and M proteins, carefully designed for optimal immunogenicity, administration and manufacturability.

Key Points: 
  • ISA106, a SARS-CoV-2 immunotherapeutic, consists of multiple SLPs derived from the S, N and M proteins, carefully designed for optimal immunogenicity, administration and manufacturability.
  • These are demonstrable ex vivo in peripheral blood mononuclear cells (PBMCs) from convalescent donors who recovered from SARS-CoV-2 infection.
  • The data support further development of ISA106 for the protection of immunocompromised people for whom currently approved SARS-CoV-2 vaccines are insufficiently protective."
  • If you would like to meet with ISA Pharmaceuticals at the above event, please contact us at [email protected] .